Richard Gaster - 09 Jun 2022 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Reporting relationship: Director
Issuer ticker: VTYX
Reported as of: 09 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2022, 17:40:21 UTC
Prior SEC filing: 20 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Christopher Krueger, as Attorney-in-Fact

Key filing fact

Richard Gaster filed Form 4 for Ventyx Biosciences, Inc. (VTYX) on 10 Jun 2022.

Key facts

This page summarizes Richard Gaster's Form 4 filing for Ventyx Biosciences, Inc. (VTYX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2022, 17:40.

Change

Previous filing in this sequence was filed on 20 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTYX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +13,301
Change %
Price: $0.000000
Shares after: 13,301
Date: 09 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,301
Exercise price: $16.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date.

SEC remarks

Dr. Gaster is a partner of venBio Global Strategic GP III, L.P. and is a member of the board of directors of the Issuer. These options are held by Dr. Gaster for the benefit of venBio Global Strategic Fund III, L.P. ("venBio III"). Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Gaster disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III, and the filing of this Form 4 shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities and Exchange Act of 1934 or any other purpose.